Bilateral Kidney Infarction Due to Primary AL Amyloidosis

A First Case Report

Fabrice Mihout, MD, Laure Joseph, Isabelle Brocheriou, MD, PhD, Véronique Leblond, MD, PhD, Shaïda Varnous, MD, PhD, Pierre Ronco, MD, PhD, and Emmanuelle Plaisier, MD, PhD

Abstract: Primary Amyloid Light-chain (AL) amyloidosis is a rare form of plasma cell dyscrasia characterized by tissue deposition of monoclonal immunoglobulin light chain. Kidney involvement is the most frequent manifestation, and patients usually present with glomerular disease.

We report an exceptional case of bilateral kidney infarcts caused by AL amyloidosis. A 34-years-old man presented with progressive dyspnea, loin pain, recurrent macroscopic hematuria, and acute kidney injury. Computed tomography showed bilateral kidney infarcts.

The diagnosis of AL amyloidosis was established on the kidney biopsy with the characterization of major vascular amyloid deposits that selectively stained with antilambda light chain antibody. An amyloid restrictive cardiomyopathy was also present, responsible for the life-threatening conduction disturbance, but without patent cardioembolic disease. The patient then underwent emergency heart transplantation, followed by a conventional chemotherapy with bortezomib, melphalan, and dexamethasone. More than 3 years later, the patient has subnormal renal function, a well-functioning heart transplant, and a sustained hematologic response.

In addition to the very uncommon presentation, this case illustrates the tremendous progress that has occurred in the management of severe forms of AL amyloidosis.

INTRODUCTION

Primary Amyloid Light-chain (AL) amyloidosis is a rare form of plasma cell dyscrasia characterized by tissue deposits commonly made of monoclonal immunoglobulin light chain.\(^1\) Involvement of the heart, kidney, liver, and autonomic nervous systems is responsible for the poor prognosis of AL amyloidosis. Patients’ survival significantly improved during the last 15 years with the use of more effective conventional-dose chemotherapy and/or autologous stem cell transplantation (ASCT).\(^2\) We report an unusual case of AL amyloidosis with bilateral kidney infarcts at presentation and predominantly renal vascular amyloid deposits, associated with a severe cardiomyopathy. This case is exceptional because it first reports bilateral kidney infarcts caused by AL amyloidosis and illustrates the groundbreaking advances in the therapy of this dreadful disease.

CASE REPORT

A 34-year-old man was referred because of acute pain of the left flank associated with macroscopic hematuria. A painless macroscopic episode was recorded 6 months earlier. Two months before admission the patient underwent a cardiac evaluation for progressive dyspnea, thoracic pain, and palpitations. Transthoracic ultrasound revealed severe hypertrophic cardiomyopathy with biventricular wall thickening and altered left ventricular ejection fraction (45%).

On admission, physical examination showed a low blood pressure of 100/50 mmHg and New York Heart Association class II heart failure. Electrocardiography showed low voltage in the limb leads without conduction defect. Acute kidney injury was present with serum creatinine level of 1.9 mg/dL (167 μmol/L), glomerular filtration rate estimated by the Modification of the Diet in Renal Disease (MDRD) equation \((167 \text{ μmol/L}, \text{glomerular filtration rate estimated by the Modification of the Diet in Renal Disease (MDRD) equation})\) and abnormal urine protein–creatinine (180 mg/mmol), and albumin–creatinine ratios (92 mg/mmol). Urine excretion of a monoclonal lambda light chain (15% of total proteinuria) associated with serum increase of free lambda light chain (912 mg/L, N 5.7–26.3) was detected. Serum lactate dehydrogenase level was 10-fold upper the normal level, brain natriuretic peptide (BNP) was 1751 ng/L (N < 0.05).

Blood cell count and serum electrolytes were normal. Renal ultrasound at presentation was unremarkable. A contrast-enhanced abdominal Computed tomography-scan performed 2 days after admission because of the recurrence of flank pains

FIGURE 1. Abdominal CT-scan showing multifocal bilateral renal infarcts.
showed multifocal bilateral renal infarcts (Figure 1), with normal renal artery and vein, and liver and spleen enlargement. Repeated transoesophageal echocardiography showed increased echogenicity and thickening of the myocardium that was highly suggestive for amyloid infiltration, without intracardiac thrombus. Mitral and aortic valve were also prominent. Holter monitor did not document paroxysmal arrhythmia or conduction defects.

A kidney biopsy was performed (Figure 2). Light microscopy showed normal glomeruli and large areas of acute tubular necrosis associated with interstitial edema and nonspecific inflammatory infiltrates. No arteriolar thrombosis was observed. Congo red stain disclosed vascular amyloid deposits, and immunofluorescence showed positive staining for lambda light chain in the kidney vessel walls only, with no labeling of the glomeruli. Electron microscopy examination confirmed fibrillar organization of the vascular deposits, but also disclosed fine fibrillar deposits in the glomerular basement membrane. In conclusion, we present the first case of bilateral kidney amyloidosis associated with prominent amyloid lesions and cardioembolic events in the occurrence of renal infarcts is difficult to assess. Although our patient presented with clinical, biochemical, and echocardiographic evidence of severe amyloid cardiomyopathy, transoesophageal echocardiography, and histological examination of native heart at transplantation failed to detect intracardiac thrombus. Conversely, no arteriolar thrombosis was observed in the biopsy kidney specimen despite the presence of vascular amyloid deposits.

In addition to its unusual renal presentation, this case underlines that the sequential therapeutic approach of heart transplantation followed by high-dose dexamethasone-based chemotherapy with or without ASCT is feasible. Such strategy should therefore be discussed in selected patients with predominant, severe cardiac involvement at diagnosis, which is the main prognostic factor in AL amyloidosis, with a median survival being less than 6 months at the stage of congestive heart failure.10 In recent series, 3-years survival was approximately 80% and median survival time ranged from 26 to 56 months in patients with AL amyloidosis treated with cardiac transplantation plus ASCT-high-dose melphalan or melphalan–prednisone.11–13 A rate being comparable to those of cardiac transplantation for other indications.

In conclusion, we present the first case of bilateral kidney infarcts due to AL amyloidosis associated with prominent massive renal vascular amyloid deposits. This patient received chemotherapy and heart transplant and 40 months later, he is doing very well, which illustrates the huge progress made in the treatment of systemic AL amyloidosis.
FIGURE 2. (A) Amorphous, green, hyaline material replacing, and expanding the normal vessel wall with partial occlusion of the lumina. Note apparent lack of glomerular involvement (original magnification ×100). Inset: Apple green birefringence of arteriole wall under polarized light after staining with Congo red (original magnification ×200). (B) Direct immunofluorescence typing with anti-light chain antibodies. Note bright staining of arterioles (arrows) with lambda light chain antibody and negative stain for kappa light chain (original magnification ×100). (C) Electron microscopy revealed amyloid deposition in glomerulus at the endothelial side of the glomerular basement membrane (arrow) (original magnification ×10000), with a fibrillary appearance on higher magnification (inset, original magnification ×100000). (D) Amorphous red material expanding the epicardic vein. The deposits are positive with Congo red (inset myocardic wall) (original magnification ×200).
REFERENCES
1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:2003;6:583–596.
2. Gatt ME, Palladini G. Light chain amyloidosis 2012: a new era. Br J Haematol. 2013;160:582–598.
3. Bergesio F, Ciciani AM, Manganaro M, et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant. 2008;23:941–951.
4. Eirin A, Irazabal MV, Gertz MA, et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012;27:1097–1101.
5. Keeling J, Teng J, Herrera GA. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84:1322–1338.
6. Perfetti V, Casarini S, Palladini G, et al. The repertoire of immunoglobulin light chains causing predominant cardiac involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012;119:144–150.
7. Hausfater P, Costedoat-Chalumeau N, Amoura Z, et al. AL cardiac amyloidosis and arterial thromboembolic events. Scand J Rheumatol. 2005;34:315–319.
8. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116:2420–2426.
9. Soma K, Takizawa M, Uozumi H, et al. A case of ST elevated myocardial infarction resulting from obstructive intramural coronary amyloidosis. Int Heart J. 2010;51:134–136.
10. Sattianayagam PT, Gibbs SD, Pinney JH, et al. Solid organ transplantation in AL amyloidosis. Am J Transplant. 2010;10:2124–2131.
11. Dey BR, Chung SS, Spitzer TR, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010;90:905–911.
12. Kristen AV, Sack FU, Schonland SO, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail. 2009;11:1014–1020.
13. Mignot A, Varnous S, Redonnet M, et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis. 2008;101:523–532.